Pfizer's (PFE) Lyrica once-daily drug met its main goal in patients with fibromyalgia, a pain...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer's (PFE) Lyrica once-daily drug met its main goal in patients with fibromyalgia, a pain condition that affects 5M Americans, in Phase III trials, enabling them to enjoy a longer period without pain than a placebo. The study is the second of three late-stage trials testing a controlled-release version of Lyrica; in the first set of testing, the medicine failed in patients with certain types of seizures. (PR)